Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment.

Front Cardiovasc Med

Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States.

Published: September 2021

There has been a rise in the prevalence of non-alcohol fatty liver disease (NAFLD) due to the popularity of western diets and sedentary lifestyles. One quarter of NAFLD patients is diagnosed with non-alcoholic steatohepatitis (NASH), with histological evidence not only of fat accumulation in hepatocytes but also of liver cell injury and death due to long-term inflammation. Severe NASH patients have increased risks of cirrhosis and liver cancer. In this review, we discuss the pathogenesis and current methods of diagnosis for NASH, and current status of drug development for this life-threatening liver disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452937PMC
http://dx.doi.org/10.3389/fcvm.2021.742382DOI Listing

Publication Analysis

Top Keywords

non-alcoholic steatohepatitis
8
liver disease
8
steatohepatitis pathogenesis
4
pathogenesis diagnosis
4
diagnosis treatment
4
treatment rise
4
rise prevalence
4
prevalence non-alcohol
4
non-alcohol fatty
4
liver
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!